253 related articles for article (PubMed ID: 15258735)
1. Elevated serum levels of N(epsilon)-carboxymethyl-lysine, an advanced glycation end product, are associated with proliferative diabetic retinopathy and macular oedema.
Boehm BO; Schilling S; Rosinger S; Lang GE; Lang GK; Kientsch-Engel R; Stahl P
Diabetologia; 2004 Aug; 47(8):1376-9. PubMed ID: 15258735
[TBL] [Abstract][Full Text] [Related]
2. Association of serum N(ε)-Carboxy methyl lysine with severity of diabetic retinopathy.
Mishra N; Saxena S; Shukla RK; Singh V; Meyer CH; Kruzliak P; Khanna VK
J Diabetes Complications; 2016 Apr; 30(3):511-7. PubMed ID: 26782022
[TBL] [Abstract][Full Text] [Related]
3. Increased levels of N(ε)- Carboxy methyl lysine (N(ε)-CML) are associated with topographic alterations in retinal pigment epithelium: A preliminary study.
Mishra N; Saxena S; Ruia S; Prasad S; Singh V; Khanna V; Staffa R; Gaspar L; Kruzliak P
J Diabetes Complications; 2016 Jul; 30(5):868-72. PubMed ID: 27039312
[TBL] [Abstract][Full Text] [Related]
4. Increased levels of vascular endothelial growth factor and advanced glycation end products in aqueous humor of patients with diabetic retinopathy.
Endo M; Yanagisawa K; Tsuchida K; Okamoto T; Matsushita T; Higuchi M; Matsuda A; Takeuchi M; Makita Z; Koike T
Horm Metab Res; 2001 May; 33(5):317-22. PubMed ID: 11440280
[TBL] [Abstract][Full Text] [Related]
5. Pentosidine and N-carboxymethyl-lysine: biomarkers for type 2 diabetic retinopathy.
Ghanem AA; Elewa A; Arafa LF
Eur J Ophthalmol; 2011; 21(1):48-54. PubMed ID: 20544678
[TBL] [Abstract][Full Text] [Related]
6. Irbesartan treatment does not influence plasma levels of the advanced glycation end products N(epsilon)(1-carboxymethyl)lysine and N(epsilon)(1-carboxyethyl)lysine in patients with type 2 diabetes and microalbuminuria. A randomized controlled trial.
Engelen L; Persson F; Ferreira I; Rossing P; Hovind P; Teerlink T; Stehouwer CD; Parving HH; Schalkwijk CG
Nephrol Dial Transplant; 2011 Nov; 26(11):3573-7. PubMed ID: 21385863
[TBL] [Abstract][Full Text] [Related]
7. Pentosidine as a biomarker for microvascular complications in type 2 diabetic patients.
Kerkeni M; Saïdi A; Bouzidi H; Letaief A; Ben Yahia S; Hammami M
Diab Vasc Dis Res; 2013 May; 10(3):239-45. PubMed ID: 23091285
[TBL] [Abstract][Full Text] [Related]
8. Role of N-ε- carboxy methyl lysine, advanced glycation end products and reactive oxygen species for the development of nonproliferative and proliferative retinopathy in type 2 diabetes mellitus.
Choudhuri S; Dutta D; Sen A; Chowdhury IH; Mitra B; Mondal LK; Saha A; Bhadhuri G; Bhattacharya B
Mol Vis; 2013; 19():100-13. PubMed ID: 23378723
[TBL] [Abstract][Full Text] [Related]
9. The advanced glycation end product N(epsilon)-carboxymethyllysine is not a predictor of cardiovascular events and renal outcomes in patients with type 2 diabetic kidney disease and hypertension.
Busch M; Franke S; Wolf G; Brandstädt A; Ott U; Gerth J; Hunsicker LG; Stein G;
Am J Kidney Dis; 2006 Oct; 48(4):571-9. PubMed ID: 16997053
[TBL] [Abstract][Full Text] [Related]
10. Serum levels of non-carboxymethyllysine advanced glycation endproducts are correlated to severity of microvascular complications in patients with Type 1 diabetes.
Miura J; Yamagishi Si; Uchigata Y; Takeuchi M; Yamamoto H; Makita Z; Iwamoto Y
J Diabetes Complications; 2003; 17(1):16-21. PubMed ID: 12505751
[TBL] [Abstract][Full Text] [Related]
11. Elevated serum levels of AGEs, sRAGE, and pentosidine in Tunisian patients with severity of diabetic retinopathy.
Kerkeni M; Saïdi A; Bouzidi H; Ben Yahya S; Hammami M
Microvasc Res; 2012 Nov; 84(3):378-83. PubMed ID: 22835520
[TBL] [Abstract][Full Text] [Related]
12. Serum levels of the advanced glycation end products Nepsilon-carboxymethyllysine and pentosidine are not influenced by treatment with the angiotensin receptor II type 1 blocker irbesartan in patients with type 2 diabetic nephropathy and hypertension.
Busch M; Franke S; Wolf G; Rohde RD; Stein G;
Nephron Clin Pract; 2008; 108(4):c291-7. PubMed ID: 18434751
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of N (epsilon)-(3-formyl-3,4-dehydropiperidino)lysine as a novel biomarker for the severity of diabetic retinopathy.
Zhang X; Lai Y; McCance DR; Uchida K; McDonald DM; Gardiner TA; Stitt AW; Curtis TM
Diabetologia; 2008 Sep; 51(9):1723-30. PubMed ID: 18587559
[TBL] [Abstract][Full Text] [Related]
14. N(carboxymethyl)lysine as a biomarker for microvascular complications in type 2 diabetic patients.
Wautier MP; Massin P; Guillausseau PJ; Huijberts M; Levy B; Boulanger E; Laloi-Michelin M; Wautier JL
Diabetes Metab; 2003 Feb; 29(1):44-52. PubMed ID: 12629447
[TBL] [Abstract][Full Text] [Related]
15. Relationship between blood levels of N-carboxymethyl-lysine and pentosidine and the severity of microangiopathy in type 2 diabetes.
Hirata K; Kubo K
Endocr J; 2004 Dec; 51(6):537-44. PubMed ID: 15644571
[TBL] [Abstract][Full Text] [Related]
16. Clinical implications of N epsilon-(carboxymethyl)lysine, advanced glycation end product, in children and adolescents with type 1 diabetes.
Hwang JS; Shin CH; Yang SW
Diabetes Obes Metab; 2005 May; 7(3):263-7. PubMed ID: 15811143
[TBL] [Abstract][Full Text] [Related]
17. Diabetic retinopathy risk correlates with intracellular concentrations of the glycoxidation product Nepsilon-(carboxymethyl) lysine independently of glycohaemoglobin concentrations.
Hammes HP; Brownlee M; Lin J; Schleicher E; Bretzel RG
Diabetologia; 1999 May; 42(5):603-7. PubMed ID: 10333054
[TBL] [Abstract][Full Text] [Related]
18. Contribution of dietary advanced glycation end products (AGE) to circulating AGE: role of dietary fat.
Davis KE; Prasad C; Vijayagopal P; Juma S; Adams-Huet B; Imrhan V
Br J Nutr; 2015 Dec; 114(11):1797-806. PubMed ID: 26392152
[TBL] [Abstract][Full Text] [Related]
19. Immunochemical quantification of crossline as a fluorescent advanced glycation endproduct in erythrocyte membrane proteins from diabetic patients with or without retinopathy.
Yamaguchi M; Nakamura N; Nakano K; Kitagawa Y; Shigeta H; Hasegawa G; Ienaga K; Nakamura K; Nakazawa Y; Fukui I; Obayashi H; Kondo M
Diabet Med; 1998 Jun; 15(6):458-62. PubMed ID: 9632118
[TBL] [Abstract][Full Text] [Related]
20. An inhibitor of advanced glycation end product formation reduces N epsilon-(carboxymethyl)lysine accumulation in glomeruli of diabetic rats.
Nakamura S; Tachikawa T; Tobita K; Aoyama I; Takayama F; Enomoto A; Niwa T
Am J Kidney Dis; 2003 Mar; 41(3 Suppl 1):S68-71. PubMed ID: 12612956
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
